| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Articles |
Ludwig Institute for Cancer Research, Stockholm Branch, S-17177 Stockholm [J. F., H. M. G., V. P. C., R. F. P.]; Department of Medical Immunology and Microbiology, Uppsala University, 75123 Uppsala [G. A.]; and Department of Pathology, Umeå University, 90187 Umeå [G. R.], Sweden
Abstract
The genes encoding the cyclin-dependent kinase inhibitors p16INK4A (CDKN2A) and p15INK4B (CDKN2B) are frequently homozygously deleted in a variety of tumor cell lines and primary tumors, including glioblastomas in which 4050% of primary tumors display homozygous deletions of these two loci. Although the role of p16 as a tumor suppressor has been well documented, it has remained less well studied whether p15 plays a similar growth-suppressing role. Here, we have used replication-defective recombinant adenoviruses to compare the effects of expressing wild-type p16 and p15 in glioma cell lines. After infection, high levels of p16 and p15 were observed in two human glioma cell lines (U251 MG and U373 MG). Both inhibitors were found in complex with CDK4 and CDK6. Expression of p16 and p15 had indistinguishable effects on U251 MG, which has homozygous deletion of CDKN2A and CDKN2B, but a wild-type retinoblastoma (RB) gene. Cells were growth-arrested, showed no increased apoptosis, and displayed a markedly altered cellular morphology and repression of telomerase activity. Transduced cells became enlarged and flattened and expressed senescence-associated ß-galactosidase, thus fulfilling criteria for replicative senescence. In contrast, the growth and morphology of U373 MG, which expresses p16 and p15 endogenously, but undetectable levels of RB protein, were not affected by exogenous overexpression of either inhibitor. Thus, we conclude that overexpression of p15 has a similar ability to inhibit cell proliferation, to cause replicative senescence, and to inhibit telomerase activity as p16 in glioma cells with an intact RB protein pathway.
This article has been cited by other articles:
![]() |
N. Zhao, G. Huang, L. Guo, and S.-H. Lu ECRG1, a Novel Candidate of Tumor Suppressor Gene in the Esophageal Carcinoma, Triggers a Senescent Program in NIH3T3 Cells Experimental Biology and Medicine, January 1, 2006; 231(1): 84 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Ding, J. R. Grammer, M. A. Nelson, J.-L. Guan, J. E. Stewart Jr., and C. L. Gladson p27Kip1 and Cyclin D1 Are Necessary for Focal Adhesion Kinase Regulation of Cell Cycle Progression in Glioblastoma Cells Propagated in Vitro and in Vivo in the Scid Mouse Brain J. Biol. Chem., February 25, 2005; 280(8): 6802 - 6815. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Song and M. F. Stinski Inhibition of Cell Division by the Human Cytomegalovirus IE86 Protein: Role of the p53 Pathway or Cyclin-Dependent Kinase 1/Cyclin B1 J. Virol., February 15, 2005; 79(4): 2597 - 2603. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Williams, J. P. Mear, H.-C. Liang, S. S. Potter, B. J. Aronow, and M. C. Colbert Large-scale reprogramming of cranial neural crest gene expression by retinoic acid exposure Physiol Genomics, October 4, 2004; 19(2): 184 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. B. Roninson Tumor Cell Senescence in Cancer Treatment Cancer Res., June 1, 2003; 63(11): 2705 - 2715. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-S. Cong, W. E. Wright, and J. W. Shay Human Telomerase and Its Regulation Microbiol. Mol. Biol. Rev., September 1, 2002; 66(3): 407 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marcotte and E. Wang Replicative Senescence Revisited J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): B257 - 269. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |